Dublin, May 19, 2026 (GLOBE NEWSWIRE) -- The "Autoimmune Collaboration and Licensing Deals 2016-2026" report has been added to ResearchAndMarkets.com's offering.
Autoimmune Collaboration and Licensing Deals
This report gives you direct access to 1,000+ real-world autoimmune partnerships, so you can see exactly how deals are structured, valued, and negotiated across the market.
Autoimmune is one of the most competitive and fragmented partnering markets in biopharma - spanning 30+ diseases, multiple modalities, and highly variable deal structures. If you're entering a deal without clear benchmarks, you're operating at a disadvantage.
Know what a "market deal" actually looks like
Without real comparables, it's easy to overpay, undersell, or misjudge partner expectations.
With this report, you can:
- Anchor your deal with real precedent
- Understand what companies are actually agreeing to - not just what's announced
- Benchmark financial terms with confidence
- Compare upfronts, milestones, and royalty structures across autoimmune deals
- Understand variability across indications and stages
- See how deals differ between RA, IBD, dermatology, and beyond
- Pressure-test your assumptions before negotiations
- Validate your structure against real transactions
- Go beyond headline numbers - see how deals are really done
Most sources stop at deal value. That's not enough.
This report gives you access to actual contract documents, so you can see:
- What rights are granted (and retained)
- How development and commercialization responsibilities are split
- How payments are triggered in practice
- Where risk, control, and flexibility sit in the agreement
- Because in autoimmune dealmaking, the structure matters as much as the price.
- Built for teams actively doing autoimmune deals
Whether you're licensing assets, partnering programs, or evaluating opportunities, this report helps you:
- Move faster with instant access to relevant comparables
- De-risk decisions using real deal evidence
- Strengthen your negotiation position
- Support internal strategy with credible market data
What you get
- 1,000+ autoimmune collaboration and licensing deals
- Coverage across 30+ autoimmune diseases
- Financial terms, including upfronts, milestones, and royalties
- Fully searchable deal directory (by company, therapy, technology)
- Direct access to SEC-filed contract documents
- 500+ pages of structured deal analysis
- The bottom line
Autoimmune dealmaking is complex - but your decision-making doesn't have to be.
Key Topics Covered:
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in autoimmune dealmaking
2.1. Introduction
2.2. Autoimmune deals over the years
2.3. Autoimmune deals by deal type
2.4. Autoimmune deals by industry sector
2.5. Autoimmune deals by stage of development
2.6. Autoimmune deals by technology type
Chapter 3 - Financial deal terms for autoimmune deals
3.1. Introduction
3.2. Disclosed financials terms for autoimmune deals
3.3. Autoimmune deal headline values
3.4. Autoimmune deal upfront payments
3.5. Autoimmune deal milestone payments
3.6. Autoimmune deal royalty rates
Chapter 4 - Leading autoimmune dealmakers and deals
4.1. Introduction
4.2. Most active in autoimmune dealmaking
4.3. List of most active dealmakers in autoimmune
4.4. Top autoimmune deals by value
Chapter 5 - Autoimmune deal contract document directory
5.1. Introduction
5.2. Autoimmune partnering deals where contract document available
Chapter 6 - Autoimmune dealmaking by therapeutic target
6.1. Introduction
6.2. Deals by autoimmune therapeutic target
Deal Directory
- Deal Directory - Autoimmune deals by company A-Z
- Deal Directory - Autoimmune deals by technology type
- Deal type definitions
For more information about this report visit https://www.researchandmarkets.com/r/davubx
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
